Reducing the Risk of Adverse Events in Patients with Type 2 Diabetes Who are Poorly Treated with Metformin Combined with Acarbose：Dipeptidyl Peptidase-4 Inhibitor is Better Than Insulin

Reducing the Risk of Adverse Events in Patients with Type 2 Diabetes Who are Poorly Treated with Metformin Combined with Acarbose：Dipeptidyl Peptidase-4 Inhibitor is Better Than Insulin

BackgroundClinically, when metformin (Met) combined with acarbose (Aca) cannot achieve the ideal hypoglycemic effect, a third drug will be usually added, such as insulin (Ins) or dipeptidyl peptidase-4 inhibitor (DPP-4i) etc., but there are few reports on the effect of triple therapy on complication...

Full description

Bibliographic Details
Main Author: SU Peng, LIU Yukun, LIANG Xiaohua, LIU Xin, YU Yaohui, HUANG Pengfei, BAI Yuru, HE Xiaoyan, SHEN Zhihong, MA Dong
Format: Article
Language:zho
Published: Chinese General Practice Publishing House Co., Ltd 2022-03-01
Series:Zhongguo quanke yixue
Subjects:
|diabetes mellitus, type 2|dipeptidyl-peptidaseⅳ inhibitors|metformin|acarbose|drug-related side effects and adverse reactions|cohort studies|retrospective studies
Online Access:https://www.chinagp.net/fileup/1007-9572/PDF/yx202202022.pdf

Similar Items

Similar Items